Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Rhythm Pharmaceuticals, Inc. (RYTM : NSDQ)

• Company Description    Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA. Number of Employees: 140

• Price / Volume Information    Yesterday's Closing Price: $3.27 Daily Weekly Monthly 20 Day Moving Average: 521,539 shares Shares Outstanding: 50.39 (millions) Market Capitalization: $164.79 (millions) Beta: 1.69 52 Week High: $22.48 52 Week Low: $3.04 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -59.23% -55.36% 12 Week -55.99% -50.54% Year To Date -67.23% -59.97%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 222 BERKELEY STREET 12TH FLOOR - BOSTON,MA 02116 USA ph: 857-264-4280 fax: 857-264-4299 hannah.deresiewicz@sternir.com http://www.rhythmtx.com

• General Corporate Information    Officers David P. Meeker - Chief Executive Officer; Director; Chairman Hunter Smith - Chief Financial Officer William T. Roberts - Chief Accounting Officer Edward T. Mathers - Director Stuart Arbuckle - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 76243J105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/02/22 Share - Related Items Shares Outstanding: 50.39 Most Recent Split Date: (:1) Beta: 1.69 Market Capitalization: $164.79 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.09 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/02/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.70 Price/Cash Flow: - Price / Sales: 35.69 EPS Growth vs. Year Ago Period: -216.67% vs. Previous Quarter: -23.53% Sales Growth vs. Year Ago Period: 4,180.00% vs. Previous Quarter: -17.56% ROE 03/31/22 - -55.66 12/31/21 - -20.80 09/30/21 - -20.19 ROA 03/31/22 - -48.91 12/31/21 - -18.61 09/30/21 - -18.22 Current Ratio 03/31/22 - 5.36 12/31/21 - 7.10 09/30/21 - 14.30 Quick Ratio 03/31/22 - 5.36 12/31/21 - 7.10 09/30/21 - 14.30 Operating Margin 03/31/22 - -3,598.16 12/31/21 - -2,207.13 09/30/21 - - Net Margin 03/31/22 - -3,598.16 12/31/21 - -2,207.13 09/30/21 - - Pre-Tax Margin 03/31/22 - -4,074.77 12/31/21 - -2,207.10 09/30/21 - -4,013.01 Book Value 03/31/22 - 4.68 12/31/21 - 5.65 09/30/21 - 6.41 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©